Physician profile
Sterling Malish
NPI 1003073776
$2,007.41
in general payments reported to CMS, 2019-2025
20 companies · $1,164 in 2025
The $1,164 reported for 2025 was more than what 87% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $160 · 2024: $683 · 2025: $1,164.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,840 · Education: $168.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,839.66 |
| Education | $167.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $292.37 | 2024-2025 | |
| Glaxosmithkline, LLC. | $258.30 | 2024-2025 | Trelegy Ellipta, Arexvy, Nucala |
| Regeneron Healthcare Solutions, INC. | $202.18 | 2024-2025 | Dupixent |
| Ambu INC. | $160.45 | 2023 | |
| Astrazeneca Pharmaceuticals LP | $134.94 | 2024-2025 | Airsupra, Fasenra, Breztri |
| Viatris Specialty LLC | $124.80 | 2025 | Yupelri |
| Philips North America LLC | $120.42 | 2024-2025 | Vest Therapy Und, (8874) Incourage |
| Verona Pharma, INC. | $113.21 | 2025 | Ohtuvayre |
| Mylan Specialty L.P. | $96.81 | 2024 | Yupelri |
| Sanofi-Aventis U.S. LLC | $84.99 | 2024 | |
| Baxter Healthcare | $74.02 | 2025 | Hillrom - Volara System |
| Takeda Pharmaceuticals U.S.A., INC. | $72.35 | 2024-2025 | Glassia |
| Actelion Pharmaceuticals US, INC. | $56.63 | 2025 | Opsumit, Uptravi |
| Insmed, INC. | $45.40 | 2025 | Arikayce, Brinsupri |
| Astellas Pharma US INC | $33.29 | 2025 | Cresemba |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $32.99 | 2024-2025 | Winrevair |
| Bayer Healthcare Pharmaceuticals INC. | $29.72 | 2024-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $28.63 | 2025 | Ofev |
| Harmony Biosciences LLC | $24.61 | 2024 | |
| Lilly USA, LLC | $21.30 | 2025 | Mounjaro, Zepbound |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sterling Malish listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.